Principal Financial Group
AMLX icon

Principal Financial Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Principal Financial Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,666
Closed -$41.7K – 2368
2024
Q1 		$41.7K Buy
14,666
+194
+1% +$2.54K ﹤0.01% 2359
2023
Q4 		$213K Buy
14,472
+126
+0.9% +$1.93K ﹤0.01% 2155
2023
Q3 		$263K Sell
14,346
-332
-2% -$7.02K ﹤0.01% 2095
2023
Q2 		$317K Sell
14,678
-319
-2% -$8.62K ﹤0.01% 2067
2023
Q1 		$440K Buy
14,997
+1,484
+11% +$51.6K ﹤0.01% 1995
2022
Q4 		$499K Buy
+13,513
New +$480K ﹤0.01% 1976

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Principal Financial Group's AMLX Position: Q2 2024 in Review

Principal Financial Group sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2024, closing a stake of 14,666 shares — an estimated $41.7K sold.

Principal Financial Group first reported a position in AMLX in Q4 2022 and held it in 6 quarters. The position peaked at $499K in Q4 2022. 119 funds tracked by Wall St. Rank hold AMLX as of Q2 2024.

  • Principal Financial Group reported no remaining Amylyx Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 14,666 Amylyx Pharmaceuticals shares in Q2 2024, an estimated $41.7K.
  • Principal Financial Group first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • Principal Financial Group's Amylyx Pharmaceuticals position peaked at $499K in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.